Related Experiment Videos
Effect of human, recombinant interleukin 2 on Punta Toro virus infections in C57BL/6 mice
J R Mead1, R A Burger, L J Yonk
1Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan 84322-5600.
Abstract:
The effect of human recombinant interleukin-2 (rIL-2) on Punta Toro virus (PTV) infection was investigated in C57BL/6 mice. Immunologic and viral parameters were assessed after mice were treated i.p. with rIL-2 for 5 days. Treatment of mice with 25000 and 12500 units/mouse of rIL-2 resulted in significant inhibition of the disease as indicated by increases in survival of mice as well as decreases in liver and serum virus titers. Serum glutamic oxalic acid and pyruvic acid transaminase levels were also lowered indicating reduced liver damage. Murine IL-2 production returned to normal or above-normal levels in rIL-2 treated mice. Natural killer cell activity was also moderately stimulated by rIL-2 treatment. Significant amounts of interferon were not detected in the sera of treated mice. Weight gain and survival rates were similar for both toxicity and normal controls indicating that rIL-2 treatments had no toxic effect.
Insights
Human recombinant interleukin-2 (rIL-2) treatment significantly improved survival and reduced liver damage in mice infected with Punta Toro virus (PTV). This immune-boosting therapy showed no toxic effects, offering a promising approach for PTV infection management.
Area of Science:
- Immunology
- Virology
- Toxicology
Background:
- Punta Toro virus (PTV) poses a significant health threat.
- Interleukin-2 (IL-2) is a cytokine known for its role in immune regulation.
Purpose of the Study:
- To investigate the therapeutic effect of human recombinant interleukin-2 (rIL-2) on PTV infection in a mouse model.
- To assess the impact of rIL-2 on immunologic and viral parameters during PTV infection.
Main Methods:
- C57BL/6 mice were infected with PTV and treated intraperitoneally with rIL-2 (25,000 and 12,500 units/mouse) for 5 days.
- Immunologic markers (IL-2 production, NK cell activity) and viral parameters (virus titers, transaminase levels) were measured.
- Survival rates and weight changes were monitored to assess disease progression and toxicity.
Main Results:
- rIL-2 treatment significantly increased mouse survival rates and decreased PTV titers in the liver and serum.
- Serum transaminase levels were reduced, indicating diminished liver damage.
- Murine IL-2 production normalized or increased, and natural killer cell activity was moderately stimulated.
- No significant toxic effects were observed; weight gain and survival were comparable to control groups.
Conclusions:
- Human recombinant interleukin-2 (rIL-2) demonstrates significant therapeutic potential against Punta Toro virus (PTV) infection in mice.
- rIL-2 treatment effectively inhibits PTV disease progression by enhancing immune responses and reducing viral load and liver damage.
- The study supports rIL-2 as a safe and effective immunomodulatory agent for managing PTV infections.